Evidence map›Paper›PMID 26408818›Full record

ArticleDiabetes/metabolism research and reviews2016

T-cell receptor repertoire variation may be associated with type 2 diabetes mellitus in humans.

Joseph A Frankl, Marie S Thearle, Cindy Desmarais, Clifton Bogardus, Jonathan Krakoff

Open access · greenAbstract read
In one paragraph

Article in Diabetes/metabolism research and reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Somatic T-cell Receptor Diversity in a Chronic Kidney Disease PatientPopulation Linked to Electronic Health Records.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Joseph A FranklObesity and Diabetes Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA.
Marie S ThearleObesity and Diabetes Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA.
Cindy DesmaraisAdaptive Biotechnologies, Seattle, WA, USA.
Clifton BogardusObesity and Diabetes Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA.
Jonathan KrakoffObesity and Diabetes Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA.
National Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · USAdaptive Biotechnologies (United States) · US

Funding

Risk Factors and Etiology of Obesity and Type 2 DiabetesZIADK069015 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KRAKOFF, JONATHAN · 2009 to 2025
$4.2M
Risk Factors and Etiology of Obesity and Type 2 DiabetesZ01DK069015 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KRAKOFF, JONATHAN M · 1986 to 2008
$436k
Intramural NIH HHS Z01 DK069015
6 · The paper itself

Abstract

backgroundRecent work in Pima Indians, a population with high rates of obesity and type 2 diabetes mellitus (T2DM), demonstrated that human leukocyte antigen haplotype DRB1*02 carriers have an increased acute insulin response and decreased risk for the development of T2DM, implicating loss of self-tolerance in the pathogenesis of T2DM. Advances in genomic sequencing have made T-cell receptor repertoire analysis a practical mode of investigation.

methodsHigh-throughput sequencing of T-cell receptor complementarity-determining region 3 was carried out in male Pima Indians with normal glucose regulation (n = 11; age = 31 ± 8 years; %fat = 30.2 ± 8.7%) and the protective DRB1*02 haplotype versus those with T2DM without DRB1*02 (n = 7; age = 34 ± 8 years; %fat = 31.2 ± 4.7%). Findings were partially replicated in another cohort by assessing the predictive ability of T-cell receptor variation on risk of T2DM in Pima Indian men (n = 27; age = 28.9 ± 7.1 years; %fat = 28.8 ± 7.1%) and women (n = 20; age = 29 ± 7.0 years; %fat = 37.1 ± 6.8%) with baseline normal glucose regulation but without the protective haplotype who were invited to follow-up examinations as frequently as every 2 years where diabetes status was assessed by a 75-g oral glucose tolerance test. Of these subjects, 13 developed diabetes.

resultsT-cell receptor complementarity-determining region 3 length was shorter in those with T2DM, and a one-nucleotide decrease in complementarity-determining region 3 length was associated with a nearly threefold increase in risk for future diabetes. The frequency of one variable gene, TRBV7-8, was higher in those with T2DM. A 1% increase in TRBV7-8 frequency was associated with a greater than threefold increase in diabetes risk.

conclusionsThese results indicate that T-cell autoimmunity may be an important component in progression to T2DM in Pima Indians.

Indexed as

AdultComplementarity Determining RegionsDiabetes Mellitus, Type 2FemaleGlucose Tolerance TestHaplotypesHLA-DRB1 ChainsHumansIndians, North AmericanLongitudinal StudiesMalePolymorphism, Single NucleotideReceptors, Antigen, T-CellComplementarity Determining RegionsHLA-DRB1*02 antigenHLA-DRB1 ChainsReceptors, Antigen, T-CellautoimmunityhumanPima Indianssurvival analysisT-cell receptortype 2 diabetes mellitus

Identifiers

PMID26408818
PMCPMC6383518
OpenAlexW2145244115

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.